{"schema_version":"1","generated_at":"2026-10-28T18:52:00.225Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jamile-shammo","json_url":"https://www.findmykol.com/kol/jamile-shammo/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jamile-shammo","name":"Jamile Shammo","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Northwestern University","institution_url":"https://www.findmykol.com/institution/northwestern-university-feinberg-school-of-medicine","city":"Chicago","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1316906779","orcid":"0009-0001-3787-1390","openalex":"A5017514064"},"summary":"Jamile Shammo is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 145 publications with 2,574 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":145,"cited_by_count":2574,"h_index":23,"latest_activity_year":2025,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT01379274","title":"A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Rush University Medical Center","source_url":"https://clinicaltrials.gov/study/NCT01379274","trial_url":"https://www.findmykol.com/trial/NCT01379274"},{"nct":"NCT00467610","title":"Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Rush University Medical Center","source_url":"https://clinicaltrials.gov/study/NCT00467610","trial_url":"https://www.findmykol.com/trial/NCT00467610"}],"source":"trials"},"payments":{"company_count":18,"program_years":{"first":2021,"last":null},"rows_total":51,"shown":3,"withheld":48,"rows":[{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":27513.33,"payment_count":15,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316906779"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":21861.12,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316906779"},{"payer":"Geron Corporation","program_year":2025,"amount_usd":17226.92,"payment_count":9,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316906779"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1316906779","source":"payments"},"prescribing":{"data_year":2024,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":42.5,"classes_total":6,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":30.2,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":13},{"class":"Folate Analog Metabolic Inhibitor","setting":"administered","share_pct":11,"drugs":[{"name":"Pemetrexed","share_pct":100}],"max_beneficiaries":11}]},{"area":"Blood & clotting","share_pct":35.8,"classes_total":3,"classes":[{"class":"Parenteral Iron Replacement","setting":"administered","share_pct":35.5,"drugs":[{"name":"Iron sucrose","share_pct":100}],"max_beneficiaries":15},{"class":"Thrombopoietin Receptor Agonist","setting":"prescribed","share_pct":0.2,"drugs":[{"name":"Promacta","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":19.9,"classes_total":2,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":18.7,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":11},{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":1.2,"drugs":[{"name":"Palonosetron hcl","share_pct":100}],"max_beneficiaries":11}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":99.7,"facility_pct":0.3},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2024026299","status":"verified"},{"title":"Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria","year":2024,"journal":"Hematology","source_url":"https://doi.org/10.1080/16078454.2024.2329030","status":"verified"},{"title":"Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators","year":2024,"journal":"Therapeutic Advances in Hematology","source_url":"https://doi.org/10.1177/20406207241307500","status":"verified"},{"title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","year":2023,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(23)00315-0","status":"verified"},{"title":"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization","year":2023,"journal":"Annals of Internal Medicine","source_url":"https://doi.org/10.7326/m22-3350","status":"verified"}],"source":"works"},"contact":{"address_1":"645 N MICHIGAN AVE STE 1020","city":"Chicago","state":"IL","zip":"606112814","phone":"312-695-6832","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1316906779","source":"identity"},"similar":[{"name":"Timothy Kuzel","slug":"timothy-kuzel","institution":"Northwestern University","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/timothy-kuzel","json_url":"https://www.findmykol.com/kol/timothy-kuzel/profile.json"},{"name":"Joel Charrow","slug":"joel-charrow","institution":"Northwestern University","specialty":"Clinical Genetics (M.D.)","url":"https://www.findmykol.com/kol/joel-charrow","json_url":"https://www.findmykol.com/kol/joel-charrow/profile.json"},{"name":"Paul Cremer","slug":"paul-cremer","institution":"Northwestern University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/paul-cremer","json_url":"https://www.findmykol.com/kol/paul-cremer/profile.json"},{"name":"Arthur Mandelin","slug":"arthur-mandelin","institution":"Northwestern University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/arthur-mandelin","json_url":"https://www.findmykol.com/kol/arthur-mandelin/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":48,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-10-17","provider_certified":"2022-10-17","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}